In the cohort that received the BA.5-containing bivalent booster, the neutralizing activity against all the omicron subvariants as compared with that against WA1/2020 was better than in the other two ...

A recent paper, currently available on bioRxiv* preprint server, reveals the potential for a common class of public antibodies to develop broad cross-neutralization against the severe acute ...

In the absence of effective treatments for COVID-19, many countries have approved the therapeutic use of blood plasma from recovering patients because it contains antibodies against the coronavirus.